Patrick Wood
Stock Analyst at Morgan Stanley
(2.99)
# 1,403
Out of 4,876 analysts
89
Total ratings
42.42%
Success rate
2.34%
Average return
Main Sectors:
Stocks Rated by Patrick Wood
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STE STERIS | Maintains: Equal-Weight | $240 → $260 | $238.53 | +9.00% | 4 | May 19, 2025 | |
| BSX Boston Scientific | Maintains: Overweight | $120 → $125 | $104.58 | +19.53% | 6 | May 16, 2025 | |
| GKOS Glaukos | Maintains: Underweight | $110 → $72 | $101.06 | -28.76% | 4 | May 6, 2025 | |
| GEHC GE HealthCare Technologies | Maintains: Equal-Weight | $86 → $78 | $74.86 | +4.19% | 6 | May 6, 2025 | |
| BDX Becton, Dickinson and Company | Maintains: Overweight | $280 → $196 | $169.97 | +15.31% | 4 | May 6, 2025 | |
| BLCO Bausch + Lomb | Maintains: Equal-Weight | $18 → $12 | $12.07 | -0.58% | 7 | May 6, 2025 | |
| TFX Teleflex | Maintains: Overweight | $191 → $173 | $119.58 | +44.67% | 5 | May 5, 2025 | |
| BAX Baxter International | Maintains: Underweight | $30 → $28 | $30.50 | -8.20% | 4 | May 5, 2025 | |
| SOLV Solventum | Maintains: Equal-Weight | $73 → $80 | $74.63 | +7.20% | 4 | Mar 5, 2025 | |
| TNDM Tandem Diabetes Care | Downgrades: Equal-Weight | $45 → $22 | $19.11 | +15.12% | 4 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $95 | $58.63 | +62.03% | 2 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $75 → $82 | $85.04 | -3.57% | 7 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $70 → $75 | $77.15 | -2.79% | 8 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $104 → $102 | $69.69 | +46.36% | 5 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $234 → $317 | $309.83 | +2.31% | 5 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $10 | $7.74 | +29.20% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $104 → $145 | $130.06 | +11.49% | 1 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $65 → $85 | $87.11 | -2.42% | 3 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $50 → $37 | $16.81 | +120.11% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $36 | $13.23 | +172.11% | 1 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $141.09 | - | 5 | Dec 11, 2017 |
STERIS
May 19, 2025
Maintains: Equal-Weight
Price Target: $240 → $260
Current: $238.53
Upside: +9.00%
Boston Scientific
May 16, 2025
Maintains: Overweight
Price Target: $120 → $125
Current: $104.58
Upside: +19.53%
Glaukos
May 6, 2025
Maintains: Underweight
Price Target: $110 → $72
Current: $101.06
Upside: -28.76%
GE HealthCare Technologies
May 6, 2025
Maintains: Equal-Weight
Price Target: $86 → $78
Current: $74.86
Upside: +4.19%
Becton, Dickinson and Company
May 6, 2025
Maintains: Overweight
Price Target: $280 → $196
Current: $169.97
Upside: +15.31%
Bausch + Lomb
May 6, 2025
Maintains: Equal-Weight
Price Target: $18 → $12
Current: $12.07
Upside: -0.58%
Teleflex
May 5, 2025
Maintains: Overweight
Price Target: $191 → $173
Current: $119.58
Upside: +44.67%
Baxter International
May 5, 2025
Maintains: Underweight
Price Target: $30 → $28
Current: $30.50
Upside: -8.20%
Solventum
Mar 5, 2025
Maintains: Equal-Weight
Price Target: $73 → $80
Current: $74.63
Upside: +7.20%
Tandem Diabetes Care
Mar 5, 2025
Downgrades: Equal-Weight
Price Target: $45 → $22
Current: $19.11
Upside: +15.12%
Feb 26, 2025
Maintains: Overweight
Price Target: $105 → $95
Current: $58.63
Upside: +62.03%
Feb 14, 2025
Maintains: Equal-Weight
Price Target: $75 → $82
Current: $85.04
Upside: -3.57%
Feb 12, 2025
Maintains: Equal-Weight
Price Target: $70 → $75
Current: $77.15
Upside: -2.79%
Dec 6, 2024
Maintains: Equal-Weight
Price Target: $104 → $102
Current: $69.69
Upside: +46.36%
Nov 11, 2024
Maintains: Overweight
Price Target: $234 → $317
Current: $309.83
Upside: +2.31%
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $18 → $10
Current: $7.74
Upside: +29.20%
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $104 → $145
Current: $130.06
Upside: +11.49%
Jul 15, 2024
Upgrades: Equal-Weight
Price Target: $65 → $85
Current: $87.11
Upside: -2.42%
Jul 15, 2024
Downgrades: Underweight
Price Target: $50 → $37
Current: $16.81
Upside: +120.11%
Dec 4, 2023
Initiates: Overweight
Price Target: $36
Current: $13.23
Upside: +172.11%
Dec 11, 2017
Upgrades: Buy
Price Target: n/a
Current: $141.09
Upside: -